Related Experiment Video
Updated: Jun 1, 2025
03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
5.2K
Continuous Glucose Monitoring vs Fingerstick Monitoring for Hemoglobin A1c Control in Veterans
Kelsey Floerchinger1, Kelley Oehlke1, Scott Bebensee1
1Veterans Affairs Sioux Falls Health Care System, South Dakota.
Summary
Continuous glucose monitors (CGMs) significantly reduced hemoglobin A1c (HbA1c) in veterans with type 2 diabetes on insulin. This technology aids in optimizing diabetes treatment and medication management for improved patient outcomes.
Area of Science:
- Endocrinology
- Diabetes Management
- Medical Technology
Background:
- Traditional diabetes self-monitoring relies on fingerstick testing.
- Continuous glucose monitors (CGMs) offer trend data for personalized treatment.
- Previous CGM research primarily focused on type 1 diabetes, excluding veterans and insulin users.
Purpose of the Study:
- To evaluate the effectiveness of CGMs in reducing HbA1c levels in veterans with type 2 diabetes on insulin therapy.
- To compare HbA1c levels before and after CGM initiation in this specific patient population.
Main Methods:
- Retrospective chart review with a crossover, self-controlled design.
- Inclusion of veterans with an active CGM prescription at the VA Sioux Falls Health Care System.
- Primary endpoint: change in HbA1c before and after CGM initiation.
Main Results:
- Mean baseline HbA1c was 8.6%; post-CGM use, it decreased to 7.64% (average reduction of 0.969, P = .0001).
- Significant reduction in HbA1c observed in veterans with type 2 diabetes on insulin therapy.
- Average reduction of 22 units in total daily insulin doses was noted.
Conclusions:
- CGM use is associated with significant HbA1c reduction in veterans with type 2 diabetes on insulin.
- CGMs enable precise medication adjustments, potentially optimizing diabetes therapy.
- Findings suggest CGMs are beneficial for patients needing HbA1c reduction and improved glucose control.
Related Concept Videos
01:15Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
01:15Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233
01:22Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
01:15Diabetes: Symptoms, Diagnosis, and Complications
500
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
500
01:22Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
01:02Glucose Homeostasis: Regulation of Blood Glucose
1.4K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.4K